Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial

Trigriluzole did not differentiate from placebo on the primary endpoint or key secondary outcome measure at the end of the 8-week randomization phase. Placebo response rates in this study were higher than expected compared to prior European randomized c... Biopharmaceuticals, Neurology Biohaven Pharmaceutical, trigriluzole, spinocerebellar ataxia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news